CVRx (CVRX) Stock Price, News & Analysis

Company Overview

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Key Stats

• Today's Range: $12.06 to $12.70
• 50-Day Range: $11.05 to $18.13
• 52-Week Range: $6.40 to $19.24
• Volume: 220,495 shs
• Average Volume: 286,393 shs
• Market Capitalization: $326.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.83
• Consensus Rating: Moderate Buy

CVRx Stock Analysis - MarketRank™

CVRx scored higher than 43% of companies evaluated by MarketBeat, and ranked 683rd out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CVRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

CVRx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CVRx are expected to grow in the coming year, from ($1.91) to ($1.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CVRx is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CVRx is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CVRx has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.47% of the float of CVRx has been sold short.

Short Interest Ratio / Days to Cover

CVRx has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in CVRx has recently increased by 3.65%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CVRx does not currently pay a dividend.

Dividend Growth

CVRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.47% of the float of CVRx has been sold short.

Short Interest Ratio / Days to Cover

CVRx has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in CVRx has recently increased by 3.65%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

CVRx has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

Search Interest

Only 8 people have searched for CVRX on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CVRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.90% of the stock of CVRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.27% of the stock of CVRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CVRX Stock Analysis - Frequently Asked Questions

How have CVRX shares performed this year?

CVRx's stock was trading at $12.67 at the beginning of the year. Since then, CVRX stock has decreased by 1.1% and is now trading at $12.53.
View the best growth stocks for 2025 here.

How were CVRx's earnings last quarter?

CVRx, Inc. (NASDAQ:CVRX) released its quarterly earnings data on Tuesday, February, 4th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.06. CVRx had a negative net margin of 116.91% and a negative trailing twelve-month return on equity of 93.06%.

When did CVRx IPO?

CVRx (CVRX) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.

How do I buy shares of CVRx?

Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CVRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CVRx investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 2/04/2025
• Today: 4/01/2025
• Next Earnings (Estimated): 4/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CVRX
• CIK: 1235912
• Web: www.cvrx.com
• Phone: 763-416-2840
• Fax: 763-416-2841
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.83
• High Stock Price Target: $23.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +42.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,970,000.00
• Net Margins: -116.91%
• Pretax Margin: -116.80%
• Return on Equity: -93.06%
• Return on Assets: -51.78%

Debt

• Debt-to-Equity Ratio: 0.69
• Current Ratio: 12.06
• Quick Ratio: 10.23

Sales & Book Value

• Annual Sales: $51.29 million
• Price / Sales: 6.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.73 per share
• Price / Book: 4.59

Miscellaneous

• Outstanding Shares: 26,036,000
• Free Float: 21,115,000
• Market Cap: $326.23 million
• Optionable: Optionable
• Beta: 1.34